Company intelligence / Profile preview

Gracecell Bio

Suzhou, China

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Gracell Biotechnologies is a clinical-stage biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary FasTCAR and TruUCAR platforms to address major industry challenges, such as long manufacturing lead times, high production costs, and limited efficacy in solid tumors. Its lead candidate, GC012F, is a dual-targeting BCMA/CD19 CAR-T therapy being evaluated for multiple myeloma and systemic lupus erythematosus. In early 2024, Gracell was acquired by AstraZeneca, significantly bolstering AstraZeneca's cell therapy pipeline and manufacturing capabilities.

Therapeutic areas: OncologyImmunology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on Gracecell Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gracecell Bio.

Explore the full profile